2. Analysis of amino acid copolymer compositions 2013-09-30
Abstract: Methods for analyzing, selecting characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, is some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard/ In some cases the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues.
3.SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES 2013-07-31
Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
Abstract: The present disclosure relates to polarized type 2 T helper (Th2) cells and methods for using such cells in the assessment of antigenic compositions.
6.CHARACTERIZATION OF N-GLYCANS USING EXOGLYCOSIDASES 2013-07-18
Abstract: The present disclosure provides methods for analyzing structure and/or composition of N-glycans. Such methods often involve digestion of N-glycans with multiple exoglycosidases. In some embodiments, N-glycans are digested with multiple exoglycosidases simultaneously. In some embodiments, N-glycans are digested with multiple exoglycosidases sequentially. In some embodiments, methods in accordance with the present disclosure involve comparison of cleavage products of N-glycans that have been digested with multiple exoglycosidases simultaneously to N-glycans that have been digested with multiple exoglycosidases sequentially.
Abstract: Methods of cloning insert sequences into cloning vectors with high efficiency and in the correct orientation are described. In one aspect, the invention features a method of producing a plasmid comprising an insert fragment and a vector fragment in a predetermined orientation. In some embodiments, the method includes cleaving a first nucleotide sequence at a plurality of sites with a first restriction enzyme to generate a first population of nucleotide fragments, the first population of nucleotide fragments comprising insert fragments and non-insert fragments, the insert fragments comprising a non-palindromic overhang at a 5' end, at a 3' end, or at both
9.EVALUATING HEPARIN PREPARATIONS FOR PHARMACEUTICAL USE 2013-07-11
Abstract: The disclosure features methods of analyzing preparations of heparin, and materials derived from heparin using strong anion exchange high performance liquid chromatography (SAX-HPLC).
We license or own a patent portfolio of over 70 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts to certain United States patents and patent applications. Our patent portfolio includes issued or pending claims covering:
*Methods and technologies for characterizing polysaccharides and other heterogeneous mixtures
*The composition of matter and use of certain heparinases, heparinase variants and other enzymes
*Methods and technologies for synthesis of polysaccharides
*The composition of matter and use of certain novel low molecular weight heparin products, including M402
*Methods to identify, analyze and characterize glycoproteins
*Methods of manufacture of certain polysaccharide, polypeptide and complex protein or biologic products
Market Data 
Markets 
AI
